Email Us
Call Us
AUSTIN, Texas – April 8, 2026 – Altogen Labs has expanded its safety assessment portfolio with computational toxicology capabilities, incorporating physiologically based pharmacokinetic (PBPK) modeling and artificial intelligence–driven toxicity prediction to strengthen early-stage risk assessment and reduce reliance on animal studies. The direction of travel in preclinical safety is clear. Regulators worldwide are encouraging new approach methodologies (NAMs), and sponsors face increasing pressure to justify animal use and to identify liabilities before committing to expensive in vivo programs. A computational screen that flags a hepatotoxicity signal in week one is worth considerably more than a finding in a 90-day study.
Altogen Labs applies these approaches alongside, not instead of, its established experimental capabilities. Computational predictions are used to prioritize compounds, inform dose selection, and design more efficient in vivo studies, which are then executed in the company’s GLP-compliant, IACUC-regulated Austin facility. The company’s NAM portfolio also includes patient-derived cell cultures and patient-derived organoids, offering human-relevant in vitro systems for efficacy and toxicity assessment. Experimental safety services span acute, sub-chronic, and chronic toxicology, in vivo LD50 studies in mice and rats, toxicokinetics, and OECD-guideline protocols covering oral, dermal, and inhalation routes, chronic toxicity, and carcinogenicity. These integrate with efficacy testing across the company’s large collection of validated CDX, PDX, and syngeneic tumor models.
Altogen Labs states that these studies ultimately serve to facilitate development of safe and effective therapeutic agents while upholding the highest scientific and ethical standards.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services to pharmaceutical, biotechnology, and academic institutions worldwide, with a large collection of validated xenograft models and extensive experience in efficacy xenograft and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com